ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

HUMA vs OTLK // OPERATING MARGIN

Humacyte Inc. (NASDAQ) VS. Outlook Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: HUMA 2 — OTLK 1
■ METRIC PARITY
operating-margins
-60.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HUMA VS. OTLK) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC HUMA OTLK SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin -30.00% 4.00% -34.00 OTLK /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin ACTIVE -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 51.1 37.0 +14.09 HUMA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $130.5M $120.1M $10.4M HUMA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR HUMA REV OTLK REV HUMA GROSS % OTLK GROSS % HUMA FCF OTLK FCF
FY 2025 $2.0M $1.4M -50.0% 4.0% -$105.9M -$51.8M
FY 2024 $0 $0 — — -$99.7M -$68.8M
FY 2023 $0 $0 — — -$73.3M -$43.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HUMA // BETA —
OTLK // BETA —